SUWON, Korea, Sept. 15, 2020 (GLOBE NEWSWIRE) — OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, today presented a poster at the TIDES: Oligonucleotides and Peptide Therapeutics 2020 Virtual Conference. The presentation entitled, “Asymmetric siRNA Therapeutics by OliX Pharmaceuticals,” highlights OliX’ proprietary asiRNA platform technology along with the preclinical/clinical development of various programs.
The Company presented the clinical development status of OLX101A, a cell-penetrating asymmetric siRNA (cp-asiRNA) targeting hypertrophic and keloid scars. OliX also presented data on ophthalmic pipelines that demonstrate the efficacy of OLX301A, targeting wet and dry age-related macular degeneration (AMD) in rodents and non-human primate disease models. In addition, OLX301D, targeting subretinal fibrosis and wet AMD, showed efficacy in relevant animal models. The Company also showcased data for its GalNAc-asiRNA platform technology for the treatment of liver diseases.
The presentation can be found on TIDES website https://tidesus2020.eventfinity.co/directories/17271/attendee/284822387.
“This data further validates